Multiple Myeloma Faceoff: Fred Hutchinson Cancer Center vs City of Hope

home / face-off / multiple-myeloma-faceoff-fred-hutchinson-cancer-center-vs-city-of-hope

Experts from the Fred Hutchinson Cancer Center and City of Hope form two teams and go head-to-head in this review of the latest datasets in the multiple myeloma treatment landscape.

Experts on MM

EP. 1: Team Introductions: MM Experts From the Fred Hutchinson Cancer Center and City of Hope

Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Vivian G. Oehler, MD;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS
September 12th 2023

An overview of the program agenda and introduction of expert panelists from the Fred Hutchinson Cancer Center and City of Hope teams.

Experts on MM

EP. 2: Biochemical and Clinical Progression: The Two Faces of Relapsed MM

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS
September 12th 2023

Andrew Cowan, MD, discusses the complexities of relapsed multiple myeloma, distinguishing between biochemical and clinical progression, analyzing survival data, and raising questions about optimal treatment strategies.

Experts on MM

EP. 3: Cross Q&A: Navigating Biochemical Relapse and MRD Resurgence in Multiple Myeloma

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS
September 19th 2023

An insightful discussion among specialists about the challenges of treating biochemical relapse and MRD resurgence in multiple myeloma patients, exploring nuanced considerations, patient collaboration, and the evolving landscape of treatment strategies.

Experts on MM

EP. 4: Cross Q&A: Balancing Progression and Lines of Therapy at Myeloma Relapse

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS
September 19th 2023

Expert insights into tailoring treatment for biochemical relapse in multiple myeloma patients, considering disease progression and the impact of various therapy lines on treatment decisions.

Experts on MM

EP. 5: REMIX Study: Ixa-Len-Dex for Relapsed/Refractory Myeloma

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS
September 26th 2023

Outcomes of the REMIX study investigating the effectiveness and tolerability of ixa-len-dex in real-world relapsed/refractory myeloma patients, exploring progression-free survival, overall response rate, and safety.

Experts on MM

EP. 6: Cross Q&A: Exploring the Role of Ixazomib in Relapsed/Refractory Multiple Myeloma

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS
September 26th 2023

Key insights on real-world applications of the REMIX study, which evaluated real-world effectiveness and tolerability of the ixazomib-based regimen in relapsed/refractory multiple myeloma.

Experts on MM

EP. 7: Ixa-Pom-Dex as Second-Line Therapy in Relapsed/Refractory MM: Alliance A061202

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS
October 3rd 2023

Rahul Banerjee, MD, FACP, discusses the Alliance A061202 trial, presenting the potential benefits and red flags of using ixazomib-pomalidomide-dexamethasone combination in relapsed myeloma treatment.

Experts on MM

EP. 8: Debate on Efficacy and Patient Selection With Ixa-Pom-Dex in Relapsed/Refractory MM

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS
October 3rd 2023

Leading experts discuss the potential benefits and challenges of using ixazomib pomalidomide-dexamethasone as a treatment option for relapsed myeloma patients, considering factors like efficacy, overall survival, and patient demographics.

Experts on MM

EP. 9: CARTITUDE-4 Study: Cilta-Cel vs Standard of Care for Lenalidomide-Refractory Multiple Myeloma

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS
October 10th 2023

Panelists review the CARTITUDE-4 study results highlighting the efficacy of cilta-cel in lenalidomide-refractory multiple myeloma, addressing implementation challenges and patient preferences in varying relapse scenarios.

Fred Hutch and City of Hope “Face Off” on Ixazomib Vs Olverembatinib in CML and Multiple Myeloma

EP. 10: Fred Hutch and City of Hope “Face Off” on Ixazomib Vs Olverembatinib in CML and Multiple Myeloma

ONCOLOGY Staff
October 19th 2023

Fred Hutch and City of Hope "Face Off" regarding presentations focusing on multiple myeloma and chronic myeloid leukemia.